Afficher la notice abrégée

Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorDE CASTRO, Nathalie
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorCHAZALLON, Corine
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorN'TAKPE, Jean-Baptiste
dc.contributor.authorTIMANA, Isabel
dc.contributor.authorESCADA, Rodrigo
dc.contributor.authorWAGNER, Sandra
dc.contributor.authorMESSOU, Eugene
dc.contributor.authorEHOLIE, Serge
dc.contributor.authorBHATT, Nilesh
dc.contributor.authorKHOSA, Celso
dc.contributor.authorLAUREILLARD, Didier
dc.contributor.authorDO CHAU, Giang
dc.contributor.authorVELOSO, Valdilea G.
dc.contributor.authorDELAUGERRE, Constance
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorANGLARET, Xavier
dc.contributor.authorMOLINA, Jean-Michel
dc.contributor.authorGRINSZTEJN, Beatriz
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorMARCY, Olivier
dc.date.accessioned2023-02-15T09:20:05Z
dc.date.available2023-02-15T09:20:05Z
dc.date.issued2022-12
dc.identifier.issn2328-8957en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/171953
dc.description.abstractEnBACKGROUND: In people with human immunodeficiency virus [HIV] presenting with advanced disease, rates of virologic success may be lower than expected. The Reflate TB2 trial did not show non-inferiority of raltegravir versus efavirenz in people with HIV (PWH) treated for tuberculosis. We aimed to identify factors associated with virologic success and higher adherence in the trial. METHODS: In this analysis, we included participants enrolled in the Reflate TB2 trial with adherence data available. The primary outcome was virologic success (HIV-1 ribonucleic acid [RNA] <50 copies/mL) at week 48, and the secondary outcome was adherence as assessed by the pill count adherence ratio. We used logistic regression to study determinants of virologic success and optimal adherence in 2 separate analyses. RESULTS: Four hundred forty-four participants were included in the present analysis. Over the 48-week follow-up period, 290 of 444 (65%) participants had a pill count adherence ratio ≥95%. At week 48, 288 of 444 (65%) participants were in virologic success. In the multivariate analysis, female sex (adjusted odds ratio [aOR], 1.77; 95% confidence interval [CI], 1.16-2.72; P = .0084), lower baseline HIV-1 RNA levels (<100 000; aOR, 2.29; 95% CI, 1.33-3.96; P = .0087), and pill count adherence ratio ≥95% (aOR, 2.38; 95% CI, 1.56-3.62; P < .0001) were independently associated with virologic success. Antiretroviral pill burden was the only factor associated with pill count adherence ratio ≥95% (OR, 0.81; 95% CI, .71-.92; P = .0018). CONCLUSIONS: In PWH with tuberculosis receiving raltegravir or efavirenz-based regimens, female sex, optimal adherence, and baseline HIV-1 RNA <100 000 copies/mL were associated with virologic success, and the number of antiretroviral tablets taken daily was a strong predictor of adherence.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enAdherence
dc.subject.enHIV viral load
dc.subject.enRaltegravir
dc.subject.enTuberculosis
dc.title.enDeterminants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
dc.title.alternativeOpen Forum Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ofid/ofac628en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36540390en_US
bordeaux.journalOpen Forum Infectious Diseasesen_US
bordeaux.volume9en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue12en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Open%20Forum%20Infectious%20Diseases&amp;rft.date=2022-12&amp;rft.volume=9&amp;rft.issue=12&amp;rft.eissn=2328-8957&amp;rft.issn=2328-8957&amp;rft.au=DE%20CASTRO,%20Nathalie&amp;CHAZALLON,%20Corine&amp;N'TAKPE,%20Jean-Baptiste&amp;TIMANA,%20Isabel&amp;ESCADA,%20Rodrigo&amp;rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_OFID_2022_De-Castro.pdf
Taille:
631.9Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée